National Institute for Cardiovascular Researches

Bologna, Italy

National Institute for Cardiovascular Researches

Bologna, Italy
SEARCH FILTERS
Time filter
Source Type

Penna C.,University of Turin | Penna C.,National Institute for Cardiovascular Researches | Perrelli M.-G.,University of Turin | Perrelli M.-G.,National Institute for Cardiovascular Researches | And 10 more authors.
Journal of Cellular and Molecular Medicine | Year: 2013

Resistance of transplanted mesenchymal stem cells (MSCs) in post-ischemic heart is limited by their poor vitality. Vascular-endothelial-growth-factor-A (VEGF-A) as such or slowly released by fibronectin-coated pharmacologically-active-microcarriers (FN-PAM-VEGF) could differently affect survival kinases and anti-apoptotic mediator (e.g. Bcl-2). Therefore VEGF-A or FN-PAM-VEGF could differently enhance cell proliferation, and/or resistance to hypoxia/reoxygenation (H/R) of MSCs. To test these hypotheses MSCs were incubated for 6-days with VEGF-A alone or with FN-PAM-VEGF. In addition, MSCs pre-treated for 24-hrs with VEGF-A or FN-PAM-VEGF were subsequently exposed to H/R (72-hrs 3% O2 and 3-hrs of reoxygenation). Cell-proliferation and post-hypoxic vitality were determined. Kinases were studied at 30-min., 1- and 3-days of treatment. Cell-proliferation increased about twofold (P < 0.01) 6-days after VEGF-A treatment, but by a lesser extent (55% increase) with FN-PAM-VEGF (P < 0.05). While MSC pre-treatment with VEGF-A confirmed cell-proliferation, pre-treatment with FN-PAM-VEGF protected MSCs against H/R. In the early phase of treatments, VEGF-A increased phospho-Akt, phospho-ERK-1/2 and phospho-PKCε compared to the untreated cells or FN-PAM-VEGF. Afterword, kinase phosphorylations were higher with VGEF, except for ERK-1/2, which was similarly increased by both treatments at 3 days. Only FN-PAM-VEGF significantly increased Bcl-2 levels. After H/R, lactate dehydrogenase release and cleaved Caspase-3 levels were mainly reduced by FN-PAM-VEGF. While VEGF-A enhances MSC proliferation in normoxia, FN-PAM-VEGF mainly hampers post-hypoxic MSC death. These different effects underscore the necessity of approaches suited to the various conditions. The use of FN-PAM-VEGF could be considered as a novel approach for enhancing MSC survival and regeneration in hostile environment of post-ischemic tissues. © 2012 The Authors. Published by Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd.


Penna C.,University of Turin | Penna C.,National Institute for Cardiovascular Researches | Granata R.,University of Turin | Tocchetti C.G.,University of Naples Federico II | And 6 more authors.
Current Drug Targets | Year: 2015

Cardiovascular diseases (CVD) are the leading cause of death, chronic illness and disability in Western countries. The most common cause of CVD derives from the harmful effects of acute myocardial ischemia and subsequent reperfusion injury. Cardioprotection against acute ischemia/ reperfusion injury is made possible by the “conditioning protocols.” Conditioning is obtained by applying a few periods of brief ischemia and reperfusion in the event of prolonged (index) ischemia that may cause myocardial infarction. Whilst the conditioning stimulus is applied before the index ischemia in ischemic pre-conditioning, it is applied after the event in post-conditioning. Pre and post- conditioning stimuli can be applied in a different/remote organ (remote pre- and post-conditioning); in this case conditioning stimulus can also be applied during the index event, in the so called remote per-conditioning. All these endogenous cardioprotective strategies recruit endogenous cytoprotective agents and factors that elicit specific cardioprotective pathways. Here, we discuss many of these cardioprotective factors compared to literature and highlight their main characteristics and mechanisms of action. Enphasis is given to endogenous cardioprotective agents acting or not on surface receptors, including chromogranin A derivatives, ghrelin-associated peptides, growth factors and cytokines, and to microvesicles and exosomes. Moreover the cardioprotective effects of gasotransmitters nitric oxide, hydrogen sulphide and carbon monoxide are reviewed. The possible clinical translation of these knowledge for future successful therapies is briefly and critically discussed. © 2015, Bentham Science Publishers.


Genuini I.,University of Rome La Sapienza | D'Ambrosi A.,University of Rome La Sapienza | Silvetti E.,University of Rome La Sapienza | De Lazzari C.,CNR Institute of Clinical Physiology | And 4 more authors.
Frontiers in Artificial Intelligence and Applications | Year: 2012

Every year in Italy more than 1000 people under 35 years old are victims of sudden cardiac death (SCD). Such an incidence is comparable to that of other Western countries. Pathologies responsible for SCD should be diagnosed as early as possible in order to have effective prevention. The pilot study described in this paper is a particular application of telecardiology. It exploits the teleconsulting paradigm in order to perform a screening in high school students aimed at preventing sudden cardiac death. © 2012 The authors and IOS Press. All rights reserved.


De Lazzari C.,CNR Institute of Clinical Physiology | De Lazzari C.,National Institute for Cardiovascular Researches | Pisanelli D.M.,CNR Institute of Cognitive Sciences and Technologies | D'Ambrosi A.,University of Rome La Sapienza | And 3 more authors.
Frontiers in Artificial Intelligence and Applications | Year: 2011

Italy has a long tradition of telemedicine experiments that may be dated back to the early Seventies and currently many different telemedicine services are implemented in the country. Cardiology is the field of health care that currently gets the greatest benefits from telemedicine and it is also a very relevant field, since it is estimated that there are about three million people affected by chronic heart failure (5% of the population). In this paper we review some of the most significant cardiac telemonitoring projects in Italy, then we show the future prospects for telecardiology and put in evidence responsibilities and legal aspects. We conclude that telecardiology, by enabling a better interaction between hospital and territory by means of teleconsulting, telemonitoring, telecare and remote access to clinical information, improves the quality of the whole health system. However, it cannot and should not replace the essential home care services, but it should be integrated properly and profitably with them. © 2011 The authors and IOS Press. All rights reserved.


De Lazzari C.,CNR Institute of Clinical Physiology | De Lazzari C.,National Institute for Cardiovascular Researches | Pisanelli D.M.,CNR Institute of Cognitive Sciences and Technologies | Genuini I.,University of Rome La Sapienza | And 4 more authors.
Proceedings of the 9th IASTED International Conference on Biomedical Engineering, BioMed 2012 | Year: 2012

It is estimated that in Italy there are about three million people affected by chronic heart failure. Cardiology is the health care field currently getting the largest benefits from telemedicine. Transmission, using wireless devices, makes possible to achieve virtual hospitalization: it is possible to anticipate the time of discharging and the patient can be remotely controlled by the central station in the ICU of the department of Medicine. Teleconsulting (i.e. a distance consulting between physicians) is applied in telecardiology, it allows the realization of a consulting between cardiology departments and remote services in the same hospital or among far-away hospitals. In this paper some of the most significant cardiac telemonitoring projects in Italy are described. Also reported, the projects involving the applications of implantable cardiac devices which can be controlled remotely. In conclusion, we sketch out the future prospects of telecardiology research and its applications in Italy.

Loading National Institute for Cardiovascular Researches collaborators
Loading National Institute for Cardiovascular Researches collaborators